U.S. Markets close in 6 hrs 17 mins

RadNet Inc (RDNT) Q1 2019 Earnings Call Transcript

Motley Fool Transcribers, The Motley Fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

RadNet Inc  (NASDAQ: RDNT)
Q1 2019 Earnings Call
May. 09, 2019, 10:30 a.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Thank you for standing by. This is the conference operator. Welcome to the RadNet First Quarter 2019 Results Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. (Operator Instructions)

I would now like to turn the conference over to Mark Stolper, Executive Vice President and Chief Financial Officer. Please go ahead sir.

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Thank you. Good morning, ladies and gentlemen, and thank you for joining Dr. Howard Berger and me today to discuss RadNet's first quarter 2019 financial results.

Before we begin today, we'd like to remind everyone of the Safe Harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated future financial and operating performance, RadNet's ability to continue to grow the business by generating patient referrals and contracts with radiology practices, recruiting and retaining technologists, receiving third-party reimbursement for diagnostic imaging services, successfully integrating acquired operations, generating revenue and adjusted EBITDA for the acquired operations as estimated, among others, are forward-looking statements within the meaning of the Safe Harbor.

Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause RadNet's actual results to differ materially from the statements contained here in. These risks and uncertainties include those risks set forth in RadNet's reports filed with the SEC from time to time including RadNet's Annual Report on Form 10K for the year ended December 31st 2018. Undue reliance should not be placed on forward-looking statements especially guidance on future financial performance which speaks only as of the date it is made. RadNet undertakes no obligation to update publicly any forward-looking statements to reflect the new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events. And with that, I'd like to turn the call over to Dr. Berger.

Howard G. Berger -- President and Chief Executive Officer

Thank you, Mark, and good morning everyone and thank you for joining us today. On today's call, Mark and I plan to provide you with highlights from our first quarter 2019 results, give you more insight into the factors which affected the performance and discuss our future strategy. After our prepared remarks, we will open the call to your questions. I'd like to thank all of you for your interest in our Company and for dedicating a portion of your day to participate in our conference call this morning.

Our performance in the first quarter was an excellent start to the year. Revenue, EBITDA, and procedural volumes exceeded our internal budgets, and in comparison to last year's first quarter, our improvement was exceptional. Our revenue increased 17.4% and our EBITDA increased 57.3% from last year's first quarter. We increased same center procedural volumes this quarter as compared with last quarter's same quarter -- last year's same quarter by 2.3%.

The strong results had a number of drivers. First, on a comparison basis to last year's first quarter, we benefited significantly from mild weather -- milder weather conditions relative to last year's quarter, with over half of our revenues coming from our Northeast and mid-Atlantic regions. Our business in the first quarter is highly sensitive to weather conditions. Second, we continue to further operationalize and improve the performance of our East Coast capitation contract with Emblem Health where we started seeing patients in October. Under the five-year contract, RadNet assumed responsibility for imaging operations in 26 AdvantageCare Physicians or ACP locations where we have committed to major upgrades and expanded services at many of these locations. These upgrades are positioning us to more effectively service the Emblem lives and affording us expansion opportunities in the future.

We continue to make efforts to assist in directing AC patients into our outpatient locations and away from hospital facilities and other competitive independent imaging centers. The more successful we are at doing this, the more profitable the contract is to us and the more savings to Emblem Health. As we continue these efforts, over the coming quarters, we expect to receive further benefits from this relationship. Both Emblem Health and RadNet are pleased with the progress to date and we are in dialogue about other ways we can work together.

Third, our quarter benefited from the integration of our acquisition of Medical Arts Radiology. As you may recall, we've acquired Medical Arts 10 multi-modality imaging centers as of October 1st. Medical Arts is one of the more established radiology practices in Long Island and the acquired centers have added additional convenient locations of service for the Emblem Health lives to which we are providing imaging services.

Medical Arts is now fully integrated into our eRAD IT platform and has adopted a number of RadNet's best practices including time and service payments, billing and collecting, scheduling pre-authorization to name just a few.

Fourth, the quarter also benefited from consolidating the operations of our New Jersey Imaging Network joint venture effective October 1st 2018. The joint venture with RWJ Barnabas, the largest health system in New Jersey, was initially established in 2012 and significantly expanded in 2015. We are tracking to exceed our projection for the incremental contribution from New Jersey Imaging Network during 2019.

Lastly, our business is beginning to see improvements from some of the infrastructure investments we made during 2018 about which we discussed on our last financial results conference call. Most notably, we invested significantly in our revenue cycle operations. We are required to collect more money than ever from patients as a result of higher deductible health plans, more complicated pre-authorization processes, more significant office visits and co-insurance.

As a result, we have recruited and hired new senior management in this area expanding customer service call center personnel and hours of operation, increased the size of our patient collection teams and invested in new tools and technology to increase productivity and billing accuracy. As a result, our DSOs are the lowest they have been in the Company's history, and we are collecting more dollars from patients than ever before.

Other infrastructure investments contributing to our performance are in the area of financial systems and information technology. Almost a year ago, we migrated to a new accounting system, Microsoft Dynamics Great Plains. This is benefiting us in more timely and detailed financial reporting that will allow our field operators and executive management to invaluable dashboards and real-time data that will provide us advantages in a competitive environment.

We also invested heavily in cyber security software and compliance systems to ensure that our patient and financial data is protected and conform to all regulatory requirements.

As I look forward to the remainder of the year, I expect other initiatives to be contributing as well. For example, in early March, we formed our second joint venture with the Dignity Health System in Ventura, California. In forming the joint venture, we contributed three of our Rolling Oaks Radiology imaging centers in Ventura, Oxnard and Camarillo. Dignity Health contributed an imaging center co-located with its St. John's Regional Medical Center in Oxnard. We're very pleased to be working more closely with Dignity and we are hopeful that we can find other opportunities to work together in other areas of California where Dignity has significant presence.

Subsequent to quarter end, we completed the acquisition of an established operator of 5 imaging centers in Bakersfield, California, a market we first entered in 2010. This operator, Kern Radiology has operated in Kern County for more than 50 years and provides radiology services to several of the local hospitals as well as the imaging centers we purchased. Over the next several quarters, we will begin working to consolidate the current assets with our existing Truxtun Radiology centers in that marketplace to maximize efficiency, streamline operations and improve the patient and referring physician experience.

Additionally, we expanded our MemorialCare joint venture in Orange County and Long Beach, California with the acquisition of a single operator in Santa An,a California and additional four locations of Orange County Diagnostics in Laguna Woods, Santa Ana, Irvine and Mission Viejo. We also recently expanded one of our two joint ventures with Cedar Sinai Medical system in the San Fernando Valley of Los Angeles. We constructed a new facility through the joint venture to expand capacity and our geographic footprint and also purchased an additional facility both located in the West Hills area of the San Fernando Valley.

At this time, I'd like to turn the call back over to Mark to discuss some of the highlights of our first quarter 2019 performance. When he is finished, I will make some closing remarks.

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Thank you, Howard. I'm now going to briefly review our first quarter 2019 performance and highlight what I believe to be some material items. I will also give some further explanation of certain items in our financial statements as well as provide some insights into some of the metrics that drove our first quarter performance. I will also reaffirm our 2019 financial guidance levels which were released in conjunction with our fourth quarter and full-year 2018 financial results. In my discussion, i will use the term adjusted EBITDA which is a non-GAAP financial measure. The Company defines adjusted EBITDA as earnings before interest, taxes, depreciation and amortization and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non controlling interests in subsidiaries and is adjusted for non-cash or extraordinary and one-time events taking place during the period. A full quantitative reconciliation of adjusted EBITDA to net income or loss attributable to RadNet Inc common shareholders is included with our earnings release.

With that said, I'd now like to review our first quarter results. For the three months ended March 31st 2019, RadNet reported revenue of $271.5 million and adjusted EBITDA of $33.1 million. Revenue increased $40.2 million or 17.4% over the prior year same quarter and adjusted EBITDA increased $12.1 million or 57.3% over the prior year same quarter. While we benefited by more favorable winter weather conditions during this year's quarter, our improved performance was also driven by strong contributions from our recent acquisitions and initiatives on the East Coast and solid overall same center procedural volume growth of 2.3%. Our results benefited from the consolidation of our New Jersey Imaging Network JV, the contribution of the Medical Arts Radiology acquisition in Long Island, and the ramp-up of Our Emblem Health capitation contract in New York.

For the first quarter of 2019, as compared with the prior year's first quarter, aggregate MRI volume increased 7.3%, CT volume increased 10.4%, PET CT volume increased 7.2%. Overall volume taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and all other exams, increased 7.6% over the prior year's first quarter.

In the first quarter of 2019, we performed 1,920,777 total procedures. The procedures were consistent with our multi-modality approach whereby 75.3% of all the work we did by volume was from routine imaging. Our procedures in the first quarter of 2019 were as follows, 259,912 MRIs as compared with 242,217 MRIs in the first quarter of 2018; 205,167 CTs as compared with 185,848 CTs in the first quarter of 2018; 10,273 PET CTs as compared with 9,587 PET CTs in the first quarter of 2018; and 1,445,425 routine imaging exams compared with 1,348,271 of all these exams in the first quarter of 2018.

Net loss for the first quarter of 2019 was $3.7 million or negative $0.08 per share compared to a net loss of $7.3 million or negative $0.15 per share reported for the three-month period ended March 31st 2018. This is based upon a weighted average number of shares outstanding in the first quarters of 49.6 million shares in 2019 and 47.8 million shares in 2018. Affecting net loss in the first quarter of 2019 were certain non-cash expenses and non-recurring items including the following, $4.5 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock, $631000 of severance paid in connection with the headcount reductions related to cost savings initiatives, and $975,000 of non-cash amortization of deferred financing costs and loan discounts related to financing fees as part of our existing credit facilities.

With regards to some specific income statement accounts, overall GAAP interest expense for the first quarter of 2019 was $12.3 million. This compares with GAAP interest expense in the first quarter of 2018 of $10 million. The increase is related to a higher debt level by about $68.1 million mainly from the addition of the New Jersey Imaging Network debt which is now added to our debt balance through the financial consolidation.

With regards to our balance sheet as of March 31st 2019, unadjusted for bond and term loan discounts, we had $679.2 million of net debt which is our total debt at par value less our cash balance. This compares with $586.6 million of net debt at March 31st 2018. A higher net debt balance at year-end is the result of consolidating New Jersey Imaging Network debt of approximately $62.4 million and having approximately $24.6 million less of cash on the balance sheet. As of March 31st 2019, we've withdrawn $41 million on our $137.5 million revolving line of credit and had a cash balance of $10.4 million.

Since quarter-end, we repaid our revolving line of credit in full through cash flow and through our financing transaction we completed on April 18th. The financing raised an incremental term loan of $100 million and added an additional capacity of $20 million under our revolving credit facility. We utilized the proceeds of the offering to repay the vast majority of the balance that existed on our revolver at that time and to fund the fees and expenses of the offering. The financing and a corresponding amendment to our credit agreement affords us more financial and operating flexibility to continue to grow our core markets by completing future tuck-in acquisitions and additional joint ventures with health systems.

This quarter, we adopted lease standard ASC 842, which amended the existing accounting standards for operating and financing leases. Under the new guidance, we were required to recognize a lease liability and right of use asset for all leases with terms in excess of 12 months. For facility and equipment operating leases, the effect of the adoption amounted to a lease liability of $455.5 million and operating lease right of use asset of $412.7 million in addition to a deferred rent liability of $35.3 million and $792,000 in unfavorable rental contract liabilities to operating lease right of use assets. For finance leases, the effect of the adoption amounted to a finance lease liability of $12.1 million which was transferred from our capital lease debt and a finance right of use asset in the amount of $14.1 million which was transferred from our PP&A.

At March 31st 2019, our accounts receivable balance was $156.8 million, an increase of $7.8 million from year-end 2018. The increase in accounts receivable is mainly the result of very strong patient volume during the last half of the month of March as well as an increase in AR from the start of the Emblem Health capitation contract. Despite the aggregate increase in our AR at month end, our days sales outstanding or DSO was 47.6 days at March 31st 2019, lower by approximately three days as of the year-end 2018.

Through March 31st 2019, we had total capital expenditures net of asset dispositions and sale of imaging center assets and joint venture interests of $32.1 million. Approximately $32.9 million was paid for in cash and we recognized approximately $888,000 in proceeds from the sale of equipment and JV equity interests. Note that our capital expenditures, as we reported, now includes the capital expenditures of New Jersey Imaging Network, as NJIN is now consolidated from a financial perspective. Also note that each year we front-load many of our capital decisions into the first quarter. So CapEx is disproportionately higher in the first half of the year.

At this time, I'd like to reaffirm our 2019 financial guidance levels, which we released in conjunction with our fourth quarter and year-end 2018 financial results. We adjusted our cash interest expense to properly incorporate the expected interest expense of New Jersey Imaging Network, which became a consolidated entity in the fourth quarter and the recently completed incremental term loan. For total net revenue, our guidance remains unchanged at $1.050 billion to $1.1 billion. For adjusted EBITDA, our guidance level remains unchanged at $155 million to $165 million. For free cash flow generation, our guidance remains unchanged at $45 million to $55 million. For capital expenditures, our guidance is unchanged at $60 million to $65 million. And for cash interest expense, we increased our revised guidance range to $43 million to $48 million of cash interest expense.

With respect to Medicare reimbursement for 2020, at this time, there is nothing to report. As is typical each year, we are expecting CMS to release a preliminary rate schedule sometime in June or July time frame at which time we will analyze CMS' proposal and our industry's lobbying group, the Association of Quality Imaging will provide CMS with our industry's feedback. At the time of our second quarter financial results call, we will be in a position to comment on CMS' proposal and its impact if any upon RadNet's future results.

At this time, I'd like to turn the call back over to Dr. Berger who will make some closing remarks.

Howard G. Berger -- President and Chief Executive Officer

Thank you, Mark. We are very enthusiastic about the future of our business and about the freestanding outpatient imaging business as a whole. Our Company and our industry expect to benefit from the continuing migration of outpatient services from hospitals into lower cost and in many cases higher quality ambulatory settings. Payers and patients are becoming more educated about the cost differential between hospital-based imaging and freestanding imaging centers. We are confident that the slow migration of patients toward ambulatory settings will continue. We are motivated and interested in working with payers and health plans to accelerate this trend.

We will continue to improve and grow our business following a disciplined strategy toward driving efficiencies that present themselves through achieving scale. For instance, our scale and concentration in our core markets have allowed us to demonstrate the power of our joint venture model with some of the more prominent health systems. We currently have about 25% of our centers in joint ventures and we see a path to increasing this to 50% in the next several years.

We will continue to drive growth and financial improvements through making operational improvements and investments in infrastructure and information technology. We will make our centers more efficient through changing protocols, upgrading and adding equipment and through creating efficiencies and scheduling pre-authorization teams and finance systems. We continue to invest in IT solutions and improve existing ones such as risk packs, critical test reporting and billing and collecting systems.

We will continue to improve the revenue cycle functions within RadNet enabling us to create more of our revenue faster and more efficiently. We will continue to encourage and participate in alternative payment models. The current default system of fee for service healthcare is going to have to change, if costs are not going to be contained in the future. We believe with our 25-plus years of experience in capitation, that we are well positioned to be the best partner for medical groups, payers and large employers looking to contain costs or achieve more cost visibility and certainty.

Lastly, we are eager to support the creation and adoption of artificial intelligent algorithms that can either improve certain aspects of our business processes or that make our radiologists more efficient, accurate and productive. We are evaluating ways to most advantageously utilize the vast data warehouse we have of images, reports and clinical data which we have accumulated over the decades we have been in business. We believe we are just scratching the surface of the opportunities that will present themselves as artificial intelligence continues to grow and refine in our industry.

I look forward to updating you on the many initiatives we discussed on our call today during our second quarter financial results in August. Operator, we are now ready for the question-and-answer portion of the call.

Questions and Answers:

Operator

Thank you, sir. We will now begin the question-and-answer session. (Operator Instructions) Our first question is from Brian Tanquilut with Jefferies. Please go ahead, sir.

Brian Tanquilut -- Jefferies -- Analyst

Hey guys. Good morning. Thank you. Congratulations, you had a really strong quarter, probably the best I've seen in 12 years of covering the stock. Howard, I guess first question for you. Towards the end of your comments, you talked about artificial intelligence. Just curious, I mean where do you see RadNet play in the AI world? And also, as probably the holder of the largest data set in imaging, how are you guys envisioning or thinking about potentially monetizing the amount of data that you have as people develop AI protocols and technologies?

Howard G. Berger -- President and Chief Executive Officer

Good morning, Brian. Thank you. Well, it's a two part question, so I'll start with the first part. Perhaps one of the more exciting things that come through the imaging industry as well as healthcare as a whole is the advancement and opportunities associated with artificial intelligence. And while I think there's a number of players that are working on various opportunities within that space from large operators or businesses like IBM through their Watson technology or smaller start-ups, RadNet is involved with looking across the spectrum of opportunities and I think that the potential impact of artificial intelligence particularly in the imaging industry which is in and of itself a technology business, are vast. On the one hand and the part perhaps that most people tend to think about is how do we use artificial intelligence to improve the radiologist performance either by making them more productive or more accurate in their diagnostic capabilities? In particular, with our business model, the focus is more on our routine imaging than the advanced imaging. When you hear a lot about the opportunities out there, they tend to focus on where artificial intelligence can impact MRI, CT and PET CT. In our particular business, that represents about 25% to 30% of our total volume, 70% to 75% of our volume though is the routine imaging comprising x-ray, mammography and ultrasound predominantly. It's precisely in those areas where I think actually for Radnet artificial intelligence may have the biggest benefit to RadNet itself and our radiologists by taking the enormous volumes of data that we have and being able to synthesize that data to perhaps firstly triage it between the normals and not normals thus allowing the radiologists to more accurately focus in on truly abnormal diagnostic possibilities as well as the ability to eventually in some cases provide a interim and then a final interpretation of those images. So if if I make a distinction between our business model and hospital settings, for example, this would be particularly beneficial for us, as a reminder, our business is primarily focused in the outpatient space where most of the patients who come to us have elective imaging that's done and a disproportionate amount of what we do is actually normal exams versus patients that are hospitalized that are generally having abnormal procedures performed.

The second place and perhaps maybe even more immediate and exciting is the use of artificial intelligence to reduce protocols particularly for MR and PET CT. Currently those exams take anywhere from 15 minutes to 20 minutes up to perhaps as long as 45 minutes. Many of the companies that we're working with including one that we've invested in ourselves have been able to reduce these scan times dramatically allowing us to be able to get better productivity and revenue per unit time on our scanners, and given the demand that we have particularly in our centers with MRI and PET CT, this could provide a substantial benefit in being able to produce more revenue for the Company without increasing our expenses.

So those will be the two focuses that we'll be looking at and I think you can anticipate in the upcoming quarters that we'll be talking more and more about it both as a tool that we use to create better margins and opportunity inside RadNet for workflow efficiency as well as perhaps investments that we make in some of these companies where we think we can leverage our volume and scale into an equity position.

Second part of your question about our data warehousing. We've been exploring for the past several quarters and answering and responding to inquiries made from various artificial intelligence designers to either use our data in return for opportunity that we get to use those algorithms inside the Company or potentially invest in them with them buying our data. There's many companies from large manufacturers down to smaller operators that are interested in having this data which is relatively unique in the healthcare industry given how much data we have and the quality of that data. One of the examples I'll note about the quality of that data going back to routine imaging is the heavy investment that we've made over the last three years in breast 3D tomosynthesis and we have the largest repository of that data in the country and which is turning out to have a substantial influence on diagnosing breast cancer earlier. So we are in the process of looking at pilot projects where we may be able to use artificial intelligence to take our data and indeed even make the diagnosis of breast cancer that much earlier which ultimately will lead to better outcomes and lower cost of healthcare system. The other area that we're looking at is talking to a couple of different potential start-ups that want to take our data and non-amortize it and then make it available in a data warehouse storage business. That would be made available to other potential buyers of that and we would be, among other things, a beneficiary of that perhaps from a financial standpoint in the way of selling that data as well as perhaps an equity investment. Now a lot of the artificial intelligence that has been developed today is using various data sets that are just made available to the public. The quality of that data and the formatting of it has not been ideal and I think we represent an opportunity or that presented to us an opportunity to create a much better use of our data in a format that allows it to be more easily managed and utilized in the development of artificial intelligence algorithms. So these are exciting opportunities and a time for us and given the size of the Company and and the amount of procedural volume that we do, I am certain that this will have a positive impact on the Company going into the future.

Brian Tanquilut -- Jefferies -- Analyst

I appreciate all that, Howard. As we think about investments, I think you also have made an investment to a company that's doing portable imaging or manufacturing portable imaging devices. So, as we think about what the retailers are doing and looking at CVS and Walgreens and how the labs are now entering those store basis with LabCorp if we're going to -- go into Walgreens, for example, I mean, do you think that there's an opportunity for RadNet or the other way to think about it I guess is for the retailers to bring you guys or some imaging capability into the box as the pharmacy models of future evolve?

Howard G. Berger -- President and Chief Executive Officer

Yes I do, Brian. I think the investment that we made which we previously talked about in Turner Imaging which we hope will be getting their FDA approval here in June represents I think a major change in the technology of how routine x-ray can be delivered in a much more comfortable and easily accessible environment such as not only pharmacies but urgent care centers or even doctors' offices. I think combining that availability with a system that truly is portable and when not in use, it can be stored on a shelf and when it does need to go into use, can virtually go into any room without worrying about shielding or other radiation they would otherwise have to be protected. And I think that's all, as you mentioned, with LabCorp, part of a way to create better access which will both lower cost and create efficiencies in the healthcare system which I believe patients and payers can benefit from substantially. All of this, particularly in the imaging space, will also have to be utilized with the value presented with artificial intelligence, particularly from the reading component of this which we are working on not only with Turner Imaging but with other vendors as I mentioned to our developing artificial intelligence specifically related to reading of plain film x-ray.

So, I expect to see substantial changes not necessarily overnight but certainly over the next five years to 10 years which could have a dramatic effect in the way imaging is delivered particularly for routine imaging into the marketplace.

Brian Tanquilut -- Jefferies -- Analyst

Appreciate that. Mark, and just a couple of questions for you. As I think about guidance, you know obviously you had a pretty good beat on the quarter. But you're maintaining guidance for the year, I know it's early in the year. Is this just conservatism? I mean, are you seeing anything on the horizon that should suggest a slowdown either in the top line or any expenses that you're anticipating will come through versus the Q1 print?

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Sure. Thanks Brian. Yes, we are not changing guidance out of conservatism. You know, we generally don't like to change guidance after first quarter results with the exception that I think we did it a year ago with the horrible winter weather in the first quarter that was so unusual or extraordinary. So, if we get further into the year and we see that it's more than likely that we'll either beat guidance range or feel that we should shift guidance that then we we absolutely do. We'll do that. But to answer your second question, we don't see anything in the coming quarters where we feel like our business will slow -- slowdown. So, we don't think that there was anything extraordinary about the first quarter results. So, we feel confident about the business and have a lot of opportunity and we have a lot of initiatives that will be contributing to the last three quarters of this year, that really didn't contribute a whole lot or anything to the first quarter, for instance, the acquisition of Kern occurred on April 1st. So that didn't contribute anything to the first quarter. We just got the second Dignity joint venture under way in Ventura County in the latter half of March, so that impact really didn't -- impact the quarter in any way. So we have a bunch of things. Also, the Emblem Health contract in Long Island and the 5 boroughs of Manhattan will also continue to have a ramp throughout the year. And we're continuing to improve on that contract and be more successful in directing the patients outside of hospitals into our imaging centers. So I think we feel optimistic about the year, and if we do continue to track way ahead of guidance, we will make appropriate adjustments.

Brian Tanquilut -- Jefferies -- Analyst

Got it. And then last one for me, Mark, as I think about same store, I mean I know you said there's nothing unusual and you guys called out better weather this year than last year. So is this a good level of same store to be thinking about? And then I guess just looking at the different modalities, I just noticed that CT has been on a downtrend. Anything to call out there on same store?

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Sure. So we've said historically that we feel comfortable with the same center level of somewhere between 1% and 3%. So we were kind of you know a little above the middle of that range this quarter at 2.3%. You know our our centers generally tend to be very busy, so in order for us to get more patients through those centers, we're changing protocols, we're getting people on and off the table more quickly, we're always figuring out with our central call call centers to figure out how to get more people on the schedule. We're doing things with cancellations to try to fill those spots in order to drive more revenue through the existing facility. So you know 1% to 3% is what we're comfortable with at this point. Obviously you know when you look at the last 11 years of the company, we've grown the top line about 11% on a compound annual basis and that's you know through things such as acquisitions and joint ventures. So we'll grow the Company much much greater than the 1% to 3%, but that's kind of the comfortable range.

Howard G. Berger -- President and Chief Executive Officer

Yes, Brian, let me add something to that too that goes back to my prior remarks is while I think there will be a benefit and a slow one as I've talked about on previous earnings calls from migration from hospitals to outpatient centers, I do want to take an opportunity to emphasize again that I think artificial intelligence will be able to help us drive better revenue and volume even with the existing utilization patterns. We have in a number of our centers a fair amount of backlog, particularly for the advanced imaging, and our ability to utilize shorter protocol times will not only be a benefit to the patients because they're on the table for less time, but will get us more revenue per unit time in these centers.

So I think that along with we're looking at tools for artificial intelligence to help us reduce the amount of no-shows by scanning our database and looking at the frequency with which people may not make their appointments and allowing us to schedule more intelligently to make certain that all of those slots are filled. So I think there's a lot of reasons for us to think that revenue which we did very well on in this quarter but mainly was driven by more favorable weather conditions and other new businesses will continue to benefit overall with some of the other external initiatives that we hope to improve our center performance level.

Brian Tanquilut -- Jefferies -- Analyst

Got it. Thanks guys.

Howard G. Berger -- President and Chief Executive Officer

Thanks Brian.

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Thanks Brian.

Operator

Our next question is from Mitra Ramgopal with Sidoti. Please go ahead.

Mitra Ramgopal -- Sidoti & Co. -- Analyst

Yes. Hi, good morning. First, I just wanted to get a sense as it relates to JVs, if you're having increased conversations with potential partners, as you mentioned, Howard, reimbursement environment still as a difficult one, and I was just wondering if you're seeing any noticeable shift now in terms of hospitals more inclined to partner with you?

Howard G. Berger -- President and Chief Executive Officer

We are starting to have some conversations. As typical with hospitals, those tend to be relatively slow and frustrating, but nonetheless, I think more and more people recognize RadNet not only as a leader in the industry, but the need for these hospitals to make imaging a much greater component of their systems' outreach as well as an opportunity for safe landing. And I want to emphasize that our desire to partner with hospital systems is not just because they look to buy into our centers or potentially us buy into theirs, but all of these systems are very active in an integrated network of providers and so that they are out there buying other physician groups where they can exert greater control of where all of that ambulatory business may wind up being directed and in particular with our relationship for the outpatient imaging. These models I believe will also be helpful as we move forward with integrated networks here to help us in designing alternative payment methods, which we're already beginning to have some conversations with payers regarding.

So I think the model which we accelerated here over the last two or three years should be something that you will hear us talk more and more about with new people that we may bring in to these opportunities, new systems as well as and perhaps even more importantly expanding the current ones we have since all of those health systems are pleased with the joint venture performance and are looking to us to continue to expand them through acquisitions or in some cases building de novo centers where appropriate.

Mitra Ramgopal -- Sidoti & Co. -- Analyst

Okay, no that's great. Thanks. And then just switching a little regarding the Emblem Health capitation contract, I believe you're making some good progress there, I was wondering if that's already starting to open up some new capitation opportunities on the East Coast?

Howard G. Berger -- President and Chief Executive Officer

We've had some preliminary conversations, given the early part of the year and focus on integrating the Emblem contract as well as the new joint ventures, we haven't ratcheted up those conversations, but we are in early discussions with what we believe are other IPAs or other payer that would look to do capitation with us on the East Coast. So I hope to be able to report more regarding those perhaps toward the middle or end of the year.

Mitra Ramgopal -- Sidoti & Co. -- Analyst

Okay. That's great. Thanks. And then just a question on the cost-saving initiatives, I know you had highlighted there was some of that in the quarter in terms of headcount et cetera and I was wondering you know how far along are you on that initiative?

Howard G. Berger -- President and Chief Executive Officer

We're pretty far along. We've we've been working on that you know toward the end of the year and very beginning of this year and it's really across virtually all of the various expense line items in the Company. So whether, as Mark has talked about, it was in revenue cycle management and new contracting for some of the services within there, whether it's purchasing for equipment and repairs and maintenance contracts, purchasing of our medical supplies, I think all of these are initiatives that we typically do on a regular basis, but which given the new business opportunities that we have, have kind of made it even more of a focus. So I think a number of those initiatives began in the first quarter and haven't been fully realized, but certainly by the second quarter or at the latest the third they will be more visible in our results.

Mitra Ramgopal -- Sidoti & Co. -- Analyst

Okay. Thanks. And then finally, just getting back, I know, Mark, you've talked about the financing in terms of the incremental term loan and adding to revolver. I was wondering if that's really a signal in terms of potential activity or discussions you're having or just more a question of just being prepared longer term in case the event comes out that you do need that capital?

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Sure. Yeah I think there were a couple of things going on there. First is, we had drawn down into the revolver in order to complete the Medical Arts transaction as well as the Kern Radiology transaction, and we wanted to clean out that revolver and give us full capacity going forward you know to have the liquidity in case something significant came along as well as to execute on a pipeline that we currently have and then we always have with respect to smaller tuck-in acquisitions in our core markets.

And then you know as we've grown the company, we really haven't increased the capacity in our revolving line of credit. And so what we did was, we added $20 million of incremental capacity. So today, we're sitting with cash in the bank and now $137.5 million worth of liquidity that we can draw down on our revolving line of credit if needed. So I think that was more just about having it available to us more so than you know something that's imminent

Mitra Ramgopal -- Sidoti & Co. -- Analyst

Okay. Thanks again for taking the questions. Great quarter.

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Thank you.

Operator

Our next question is from John Ransom with Raymond James. Please go ahead, sir.

John Ransom -- Raymond James -- Analyst

Hey guys. I mean we've seen a little bit of an uptick in M&A interest from those who are not RadNet, you know, as the industry has stabilized. Let's say hypothetically there were $10 million to $20 million EBITDA deal that would put you in a new state. Can you do that deal today at an arbitrage to where you're currently trading on EBITDA?

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Hey John, good morning. Yes, we have seen an increase in interest in radiology in general as CMS has kind of stabilized rates. As you're aware, 2019 was the fourth year in a row where Medicare essentially left our pricing unchanged and so I think that stability has given more confidence to private equity firms and others looking at investing in the imaging industry. We've seen a lot of that activity however directed toward the consolidation of professional entities, many of them hospital-based contracts, hospital reading contracts and some of those also reading outpatient facilities.

There have been a couple of deals recently where outpatient imaging centers like ours have traded at multiples that have historically been high relative to what we've purchased out there. I think that's good for the industry. I think it's terrific that new capital, smart capital is being put into the industry. We do not see that as a threat though to our ability to continue to acquire. As you're aware most of our -- to date all of our capital has been put into our existing or directed into our existing core markets and we've expanded those core markets contiguously you know over time and in those situations we are not seeing competition for those assets. You know the private equity firms and the other companies who are consolidating have opportunity in other areas of the country and I think are choosing not to try to compete against RadNet particularly because of our market concentration in all of our core markets.

We have from time to time looked at planting flags in other areas of the country when some of these assets have become available and that just hasn't been the right time at the right price with the right assets. Much of this is you know about culture and you know an opportunity where if we were going to plant a new flag in a different area of the country we wanted to have visibility that we could then take that asset or that platform and grow it substantially from that point. And when we've compared some of these opportunities to opportunities that we had in our existing core markets, we've chosen to direct our capital to existing markets. So I guess it's a long winded answer to say, yes, we will look at opportunities outside of the six states that we're currently in, but they have to be unique in terms of the right price, the right operator, the right culture and the belief and the conviction that we'd have to have that we could then take that platform and grow it into another "core market" for RadNet.

John Ransom -- Raymond James -- Analyst

I mean that's a great elegant answer. I guess the only thing I would add to that is you're only in a handful of states and so the vicissitudes of a certain state whether it's weather or state regulatory action are more pronounced. And you're also in a couple of states that aren't necessarily known for being super business friendly. So I just wonder how you think about the opportunity cost of maybe being more geographically -- I guess the regional densification and the return on capital when you buy another five centers in a place where you have 50. But what about the thought that maybe we're just a little too much New York and California long-term?

Howard G. Berger -- President and Chief Executive Officer

I think your point is a good point but I'd like to emphasize a couple of things. While we're only in five or six states, it's where 25% of the population lives and our business is very much driven by patient volume. So I think that's an important element there. The second thing is that while it sounds attractive to go into another state, I think as Mark pointed out, diversifying just for the sake of diversifying doesn't necessarily gain us a lot unless we think there is a path to creating a similar kind of presence and intensity like we have in the markets that we're in right now. And so those kind of opportunities don't allow us leverage with the payers, they don't allow us the leverage from an operational standpoint and perhaps even more importantly we become less attractive to a health system that may be looking to expand their footprint in a given market and need a lot of centers as part of the access arrangement that they want in order to handle population health and I think that's something we haven't talked about very much here, but which I see as a long-term opportunity here that population health will be a factor in the revenue opportunities that we have and the ability to have access at the scale that we do in five of our states may be something that is almost irreplaceable in a lot of these markets for handling large patient populations which again are a hallmark of the states that we're in. It doesn't mean we wouldn't look at an opportunity particularly with a large health system to perhaps joint venture elsewhere or a larger imaging operator that had a good footprint in a market. But I think one of the things that we've been able to do over the years here is grow in a very judicious manner which has allowed us to delever the company from a financial standpoint and given us I think the opportunity to continue to invest and grow the platform which at least our lenders who are out there supporting us seem very confident in. So I wouldn't rule out anything, but I want to continue to be prudent in the way we grow this company mostly mindful of the fact that our leverage ratio is foremost in our mind.

John Ransom -- Raymond James -- Analyst

Well, I would say you know my highly unscientific assessment leaves that about 80% of the large healthcare service deals over the past five years have not worked. I'm usually getting on people for being too aggressive versus being too cautious. So, I'm perfectly aware I'm a total hypocrite. The other question is, is there any what I'd call Moonshot technology that you're concerned about that would render some of your physical assets obsolete and I'm not thinking about mobile imaging devices that use Moore's Law and portability and are there things like that that if they're interesting that are kind of in the R&D stage that we may not necessarily see?

Howard G. Berger -- President and Chief Executive Officer

Other than the x-ray technology that I talked about in and that's not new technology as much as it is just kind of mobilizing or making it portable and the opportunities along those lines maybe more actually in areas outside of the United States, third world countries et cetera. But in terms of really the advanced imaging, I don't see anything on the horizon that would give us the value proposition that things like MR and PET scanning and CT have, I think the manufacturers are continuing to evolve those technologies and make opportunities within those systems that will afford greater diagnostic accuracy as well as earlier detection which plays I think into the hand of what I see long term for population health management. So, I think all the manufacturers who we utilize and who I follow are looking for the various products in their inventory to continue to grow even with some of the challenges that are out there right now.

We happen to be in the catbird seat with that, at least in the outpatient arena, we're the largest purchasers of equipment in the country. So, we're getting very favorable rates but more importantly we have very good insight. About four years ago, we hired a nationally recognized radiologist whose only function inside the company is to evaluate technology both for our own internal use as well as to create visibility for us into the future. And he is very much aligned with all the major manufacturers out there. So the visibility that we have comes not just from what we read about in the papers but with somebody who's actually helping in the development of this technology internally with the manufacturers.

So, I think we're in a pretty good position right now and I believe these tools are just going to be more and more utilized as the industry both from the general healthcare standpoint and imaging in particular moves more and more into preventative screening and population health.

John Ransom -- Raymond James -- Analyst

Thank you. Thank you for that. That's all for me.

Howard G. Berger -- President and Chief Executive Officer

Thank you, John.

Operator

(Operator Instructions). There are no further questions registered at this time. I would like to turn the conference back over to Dr. Berger for any closing remarks.

Howard G. Berger -- President and Chief Executive Officer

I'd again like to take this opportunity to thank all of our shareholders for their continued support and in particular the employees of RadNet for their dedication and hard work. Management will continue to endeavor to be the market leader that provides great services with an appropriate return on investment for all stakeholders. Thank you for your time today and I look forward to our next call.

Duration: 65 minutes

Call participants:

Mark D. Stolper -- Executive Vice President and Chief Financial Officer

Howard G. Berger -- President and Chief Executive Officer

Brian Tanquilut -- Jefferies -- Analyst

Mitra Ramgopal -- Sidoti & Co. -- Analyst

John Ransom -- Raymond James -- Analyst

More RDNT analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

More From The Motley Fool

Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.